SCHEMBL30968937

SCHEMBL30968937

CS(=O)(=O)c1c(Cl)ccc2cc[nH]c12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AHR P35869 2/20 0.44
▸ NR3C1 P04150 1/20 0.42
▸ PGR P06401 1/20 0.42
▸ NR3C2 P08235 1/20 0.42
▸ AR P10275 1/20 0.42
▸ TNF P01375 1/20 0.42
▸ RIPK1 Q13546 1/20 0.42
▸ BRD4 O60885 1/20 0.36
▸ TAF1 P21675 1/20 0.36
▸ BRPF1 P55201 1/20 0.36
▸ CREBBP Q92793 1/20 0.36
▸ CECR2 Q9BXF3 1/20 0.36
▸ BRD9 Q9H8M2 1/20 0.36
▸ GLP1R P43220 1/20 0.33
▸ KEAP1 Q14145 1/20 0.33
▸ CMA1 P23946 1/20 0.32
▸ PDPK1 O15530 1/20 0.32
▸ CCR8 P51685 1/20 0.31
▸ BCHE P06276 2/20 0.31
▸ ESR1 P03372 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25596762 0.79 NR3C1 (0.42) AHRNR3C1PGRNR3C2AR
SCHEMBL25596734 0.79 NR3C1 (0.42) AHRNR3C1PGRNR3C2AR
SCHEMBL30456277 0.75 KEAP1 (0.51) NR3C1PGRNR3C2ARBRD4
SCHEMBL25596753 0.75 NR3C1 (0.40) NR3C1PGRNR3C2ARTNF
SCHEMBL25363572 0.71 NR3C1 (0.40) NR3C1PGRNR3C2ARKEAP1
SCHEMBL31122401 0.71 NR3C1 (0.40) NR3C1PGRNR3C2ARKEAP1
SCHEMBL17659438 0.71 AHR (0.52) AHRNR3C1PGRNR3C2AR
SCHEMBL877284 0.70 AHR (0.43) AHRNR3C1PGRNR3C2AR
SCHEMBL476686 0.70 TNF (0.63) AHRTNFRIPK1BRD4TAF1
SCHEMBL30260903 0.70 TNF (0.63) AHRTNFRIPK1BRD4TAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250223307-A1 MDM2/MDMX DOUBLE-TARGET INHIBITOR COMPOUND, PRODRUG, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF GLOBAL HEALTH DRUG DISCOVERY INSTITUTE (CN) 2025-07-10 — — US disclosed
EP-4582420-A1 MDM2/MDMX DOUBLE-TARGET INHIBITOR COMPOUND, PRODRUG, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF Global Health Drug Discovery Institute (CN) 2025-07-09 — — EP disclosed
CN-118063438-A MDM2/MDMX double-target inhibitor compound, prodrug, pharmaceutical composition, preparation method and application thereof 北京华益健康药物研究中心 2024-05-24 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250223307-A1 MDM2/MDMX DOUBLE-TARGET INHIBITOR COMPOUND, PRODRUG, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF MDM2, TP53, TP53BP1 AHR 1469/4885NR3C1 3348/4885PGR 1684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback